The estimated Net Worth of Alexander J Sarissa Capital... is at least $31.7 Миллион dollars as of 15 June 2023. Alexander Capital owns over 62,000 units of Ironwood Pharmaceuticals Inc stock worth over $31,654,950 and over the last 4 years Alexander sold IRWD stock worth over $0.
Alexander has made over 7 trades of the Ironwood Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Alexander bought 62,000 units of IRWD stock worth $814,060 on 15 June 2023.
The largest trade Alexander's ever made was buying 775,000 units of Ironwood Pharmaceuticals Inc stock on 3 March 2021 worth over $7,757,750. On average, Alexander trades about 65,080 units every 33 days since 2021. As of 15 June 2023 Alexander still owns at least 7,277,000 units of Ironwood Pharmaceuticals Inc stock.
You can see the complete history of Alexander Capital stock trades at the bottom of the page.
Over the last 15 years, insiders at Ironwood Pharmaceuticals Inc have traded over $83,928,361 worth of Ironwood Pharmaceuticals Inc stock and bought 2,478,676 units worth $24,100,589 . The most active insiders traders include Llc Fmr, Bryan E Roberts и Alexander J Denner. On average, Ironwood Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $239,611. The most recent stock trade was executed by Minardo John on 12 August 2024, trading 9,910 units of IRWD stock currently worth $42,316.
ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b
Ironwood Pharmaceuticals Inc executives and other stock owners filed with the SEC include: